title: Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
authors.forename: Carmela
authors.initials: C
authors.lastname: Pinnetti
authors.forename: Silvia
authors.initials: S
authors.lastname: Baroncelli
authors.forename: Paola
authors.initials: P
authors.lastname: Villani
authors.forename: Massimo
authors.initials: M
authors.lastname: Fantoni
authors.forename: Valerio
authors.initials: V
authors.lastname: Tozzi
authors.forename: Andrea
authors.initials: A
authors.lastname: De Luca
authors.forename: Roberto
authors.initials: R
authors.lastname: Cauda
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Anzidei
authors.forename: Maria
authors.initials: M
authors.lastname: Cusato
authors.forename: Mario
authors.initials: M
authors.lastname: Regazzi
authors.forename: Marco
authors.initials: M
authors.lastname: Floridia
authors.forename: Enrica
authors.initials: E
authors.lastname: Tamburrini
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011760:Pyrrolidinones / Q000008:administration & dosage*; D012367:RNA, Viral / Q000097:blood*; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D019562:Viral Load; D014766:Viremia
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D000225:Adenine